[1]
|
Zhou, P., Yang, X.L., Wang, X.G., Hu, B., et al. (2020) A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature, 579, 270-273. https://doi.org/10.1038/s41586-020-2012-7
|
[2]
|
Bloom, J.D. (2021) Recovery of Deleted Deep Sequencing Data Sheds More Light on the Early Wuhan SARS-CoV-2 Epidemic. Molecular Biology and Evolution, 38, 5211-5224. https://doi.org/10.1093/molbev/msab246
|
[3]
|
Allam, Z. (2020) The First 50 Days of COVID-19: A Detailed Chronological Timeline and Extensive Review of Literature Documenting the Pandemic. In: Allam, Z., Surveying the COVID-19 Pandemic and its Implications, Elsevier, Amsterdam, 1-7. https://doi.org/10.1016/B978-0-12-824313-8.00001-2
|
[4]
|
Weiss, S.R. and Navas-Martin, S. (2005) Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus. Microbiology and Molecular Biology Reviews: MMBR, 69, 635-664. https://doi.org/10.1128/MMBR.69.4.635-664.2005
|
[5]
|
Peiris, J.S., Yuen, K.Y., Osterhaus, A.D. and Stöhr, K. (2003) The Severe Acute Respiratory Syndrome. The New England Journal of Medicine, 349, 2431-2441. https://doi.org/10.1056/NEJMra032498
|
[6]
|
Sampathkumar, P., Temesgen, Z., Smith, T.F. and Thompson, R.L. (2003) SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures. Mayo Clinic Proceedings, 78, 882-890. https://doi.org/10.4065/78.7.882
|
[7]
|
Centers for Disease Control and Prevention. Middle East Respiratory Syndrome (MERS). https://www.cdc.gov/coronavirus/mers/about/index.html
|
[8]
|
Azhar, E.I., Hui, D., Memish, Z.A., Drosten, C. and Zumla, A. (2019) The Middle East Respiratory Syndrome (MERS). Infectious Disease Clinics of North America, 33, 891-905. https://doi.org/10.1016/j.idc.2019.08.001
|
[9]
|
Ramadan, N. and Shaib, H. (2019) Middle East Respiratory Syndrome Coronavirus (MERS-CoV): A Review. Germs, 9, 35-42. https://doi.org/10.18683/germs.2019.1155
|
[10]
|
Li, X. (2013) Analysis of Six Patients with Unknown Viruses. Master Thesis, Kunming Medical University, Kunming. https://www.documentcloud.org/documents/6981198-Analysis-of-Six-Patients-With-Unknown-Viruses.html
|
[11]
|
Yuan, J.-F., Li, Y., Zhang, H.-J., Zhou, P., Ke, Z.-H., Zhang, Y.-Z. and Shi, Z.-L. (2009) Indirect Enzyme-Linked Immunosorbent Assay Based on the Nucleocapsid Protein of SARS-Like Coronaviruses. Virologica Sinica, 24, 146-151. https://doi.org/10.1007/s12250-009-3037-0
|
[12]
|
Zhou, P., Yang, X. L., Wang, X. G., Hu, B., et al. (2020) Addendum: A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature, 588, E6. https://doi.org/10.1038/s41586-020-2951-z
|
[13]
|
Rahalkar, M.C. and Bahulikar, R.A. (2020) Lethal Pneumonia Cases in Mojiang Miners (2012) and the Mineshaft Could Provide Important Clues to the Origin of SARS-CoV-2. Frontiers in Public Health, 8, Article ID: 581569. https://doi.org/10.3389/fpubh.2020.581569
|
[14]
|
Speciale, A.C. (2021) Commentary: Lethal Pneumonia Cases in Mojiang Miners (2012) and the Mineshaft Could Provide Important Clues to the Origin of SARS-CoV-2. Frontiers in Public Health, 9, Article ID: 702199. https://doi.org/10.3389/fpubh.2021.702199
|
[15]
|
Ge, X.Y., Wang, N., Zhang, W., Hu, B., et al. (2016) Coexistence of Multiple Coronaviruses in Several Bat Colonies in an Abandoned Mineshaft. Virologica Sinica, 31, 31-40. https://doi.org/10.1007/s12250-016-3713-9
|
[16]
|
Mallapaty S. (2021) Closest Known Relatives of Virus behind COVID-19 Found in Laos. Nature, 597, 603. https://doi.org/10.1038/d41586-021-02596-2
|
[17]
|
Zhou, H., Ji, J., Chen, X., Bi, Y., et al. (2021) Identification of Novel Bat Coronaviruses Sheds Light on the Evolutionary Origins of SARS-CoV-2 and Related Viruses. Cell, 184, 4380-4391.E14. https://doi.org/10.1016/j.cell.2021.06.008
|
[18]
|
Hu, B., Ge, X., Wang, L.F. and Shi, Z. (2015) Bat Origin of Human Coronaviruses. Virology Journal, 12, Article No. 221. https://doi.org/10.1186/s12985-015-0422-1
|
[19]
|
Guan, Y., Zheng, B.J., He, Y.Q., Liu, X.L., et al. (2003) Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China. Science (New York, N.Y.), 302, 276-278. https://doi.org/10.1126/science.1087139
|
[20]
|
Lau, S.K., Woo, P.C., Li, K.S., Huang, Y., et al. (2005) Severe Acute Respiratory Syndrome Coronavirus-Like Virus in Chinese Horseshoe Bats. Proceedings of the National Academy of Sciences of the United States of America, 102, 14040-14045. https://doi.org/10.1073/pnas.0506735102
|
[21]
|
Al Mutair, A. and Ambani, Z. (2020) Narrative Review of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection: Updates and Implications for Practice. The Journal of International Medical Research, 48. https://doi.org/10.1177/0300060519858030
|
[22]
|
Ge, X.Y., Li, J.L., Yang, X.L., Chmura, A.A., et al. (2013) Isolation and Characterization of a Bat SARS-Like Coronavirus That Uses the ACE2 Receptor. Nature, 503, 535-538. https://doi.org/10.1038/nature12711
|
[23]
|
Yang, X.L., Hu, B., Wang, B., Wang, M.N., et al. (2015) Isolation and Characterization of a Novel Bat Coronavirus Closely Related to the Direct Progenitor of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 90, 3253-3256. https://doi.org/10.1128/JVI.02582-15
|
[24]
|
Wu, Z., Yang, L., Yang, F., Ren, X., et al. (2014) Novel Henipa-Like Virus, Mojiang Paramyxovirus, in Rats, China, 2012. Emerging Infectious Diseases, 20, 1064-1066. https://doi.org/10.3201/eid2006.131022
|
[25]
|
Chen, S., Qing, J., Liu, Z., Liu, Y., et al. (2020) Multilocus Phylogeny and Cryptic Diversity of White-Toothed Shrews (Mammalia, Eulipotyphla, Crocidura) in China. BMC Evolutionary Biology, 20, Article No. 29. https://doi.org/10.1186/s12862-020-1588-8
|
[26]
|
Yin, J.X., Geater, A., Chongsuvivatwong, V, et al. (2008) Predictors for Presence and Abundance of Small Mammals in Households of Villages Endemic for Commensal Rodent Plague in Yunnan Province, China. BMC Ecology, 8, Article No. 18. https://doi.org/10.1186/1472-6785-8-18
|
[27]
|
Rissanen, I., Ahmed, A.A., Azarm, K., et al. (2017) Idiosyncratic Mòjiāng Virus Attachment Glycoprotein Directs A Host-Cell Entry Pathway Distinct from Genetically Related Henipaviruses. Nature Communications, 8, Article No. 16060. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510225/pdf/ncomms16060.pdf https://doi.org/10.1038/ncomms16060
|
[28]
|
Da Silva, S.C., Yan, L., Dang, H.V., Xu, K., et al. (2021) Functional Analysis of the Fusion and Attachment Glycoproteins of Mojiang Henipavirus. Viruses, 13, Article 517. https://www.mdpi.com/1999-4915/13/3/517/htm https://doi.org/10.3390/v13030517
|
[29]
|
Armengaud, J., Delaunay-Moisan, A., Thuret, J.Y., van Anken, E., et al. (2020) The Importance of Naturally Attenuated SARS-CoV-2 in the Fight against COVID-19. Environmental Microbiology, 22, 1997-2000. https://doi.org/10.1111/1462-2920.15039
|
[30]
|
Taubenberger, J.K. and Morens, D.M. (2006) 1918 Influenza: The Mother of All Pandemics. Emerging Infectious Diseases, 12, 15-22. https://doi.org/10.3201/eid1209.05-0979
|
[31]
|
Tumpey, T.M., Basler, C.F., Aguilar, P.V., Zeng, H., et al. (2005) Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus. Science (New York, N.Y.), 310, 77-80. https://doi.org/10.1126/science.1119392
|
[32]
|
Yang, W., Petkova, E. and Shaman, J. (2014) The 1918 Influenza Pandemic in New York City: Age-Specific Timing, Mortality, and Transmission Dynamics. Influenza and Other Respiratory Viruses, 8, 177-188. https://doi.org/10.1111/irv.12217
|
[33]
|
Hsueh, P.R., Huang, L.M., Chen, P.J., Kao, C.L. and Yang, P.C. (2004) Chronological Evolution of IgM, IgA, IgG and Neutralisation Antibodies after Infection with SARS-Associated Coronavirus. Clinical Microbiology and Infection, 10, 1062-1066. https://doi.org/10.1111/j.1469-0691.2004.01009.x
|
[34]
|
Ko, J.H., Müller, M.A., Seok, H., Park, G.E., et al. (2017) Suggested New Breakpoints of Anti-MERS-CoV Antibody ELISA Titers: Performance Analysis of Serologic Tests. European Journal of Clinical Microbiology & Infectious Diseases, 36, 2179-2186. https://doi.org/10.1007/s10096-017-3043-3
|
[35]
|
Padoan, A., Sciacovelli, L., Basso, D., Negrini, D., et al. (2020) IgA-Ab Response to Spike Glycoprotein of SARS-CoV-2 in Patients with COVID-19: A Longitudinal Study. Clinica Chimica Acta, 507, 164-166. https://doi.org/10.1016/j.cca.2020.04.026
|
[36]
|
Yu, H.Q., Sun, B.Q., Fang, Z.F., Zhao, J.C., et al. (2020) Distinct Features of SARS-CoV-2-Specific IgA Response in COVID-19 Patients. The European Respiratory Journal, 56, Article ID: 2001526. https://doi.org/10.1183/13993003.01526-2020
|
[37]
|
Tran, T., Le, T.H., Nguyen, T. and Hoang, V.M. (2020) Rapid Response to the COVID-19 Pandemic: Vietnam Government’s Experience and Preliminary Success. Journal of Global Health, 10, Article ID: 020502. https://doi.org/10.7189/jogh.10.020502
|
[38]
|
Ha, B., Ngoc Quang, L., Mirzoev, T., Tai, N.T., Thai, P.Q. and Dinh, P.C. (2020) Combating the COVID-19 Epidemic: Experiences from Vietnam. International Journal of Environmental Research and Public Health, 17, Article 3125. https://doi.org/10.3390/ijerph17093125
|
[39]
|
Mallapaty, S. (2021) Has COVID Peaked? Maybe, but It’s Too Soon to Be Sure. Nature, 591, 512-513. https://doi.org/10.1038/d41586-021-00705-9
|
[40]
|
Bhattacharjee, A., Kumar, M. and Patel, K.K. (2021) When COVID-19 Will Decline in India? Prediction by Combination of Recovery and Case Load Rate. Clinical Epidemiology and Global Health, 9, 17-20. https://doi.org/10.1016/j.cegh.2020.06.004
|
[41]
|
Vu, D., Nguyen, T. and Hoang, A. (2021) Spatial Clustering Analysis of the COVID-19 Pandemic: A Case Study of the Fourth Wave in Vietnam. Geography, Environment, Sustainability, 14, 140-147. https://doi.org/10.24057/2071-9388-2021-086
|
[42]
|
Fukui, M., Kawaguchi, K. and Matsuura, H. (2020) Does TB Vaccination Reduce COVID-19 Infection? No Evidence from a Regression Discontinuity Analysis. medRxiv 2020.04.13.20064287. https://doi.org/10.1101/2020.04.13.20064287
|
[43]
|
Escobar, L.E., Molina-Cruz, A. and Barillas-Mury, C. (2020) BCG Vaccine Protection from Severe Coronavirus Disease 2019 (COVID-19). Proceedings of the National Academy of Sciences of the United States of America, 117, 17720-17726. (Erratum in: Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27741-27742). https://doi.org/10.1073/pnas.2008410117
|
[44]
|
Urashima, M., Otani, K., Hasegawa, Y. and Akutsu, T. (2020) BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study. International Journal of Environmental Research and Public Health, 17, Article 5589. https://doi.org/10.3390/ijerph17155589
|
[45]
|
Thangaraj, J., Yadav, P., Kumar, C. G., Shete, A., et al. (2022) Predominance of Delta Variant among the COVID-19 Vaccinated and Unvaccinated Individuals, India, May 2021. The Journal of Infection, 84, 94-118. https://doi.org/10.1016/j.jinf.2021.08.006
|
[46]
|
Yang, W. and Shaman, J. (2022) COVID-19 Pandemic Dynamics in India, the SARS-CoV-2 Delta Variant and Implications for Vaccination. Journal of the Royal Society Interface, 19, Article ID: 20210900. https://doi.org/10.1098/rsif.2021.0900
|
[47]
|
Del Rio, C., Malani, P.N. and Omer, S.B. (2021) Confronting the Delta Variant of SARS-CoV-2, Summer 2021. JAMA, 326, 1001-1002. https://doi.org/10.1001/jama.2021.14811
|
[48]
|
Novelli, G., Colona, V.L. and Pandolfi, P.P. (2021) A Focus on the Spread of the Delta Variant of SARS-CoV-2 in India. The Indian Journal of Medical Research, 153, 537-541. https://doi.org/10.4103/ijmr.ijmr_1353_21
|
[49]
|
Johns Hopkins University, Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html
|
[50]
|
Le, H.T. (August 11, 2021) Delta Variant Outbreak Challenges Vietnam’s COVID-19 Response Strategy. Brookings Institution. https://www.brookings.edu/blog/order-from-chaos/2021/08/11/delta-variant-outbreak-challenges-vietnams-covid-19-response-strategy/
|
[51]
|
Nguyen, T.P., Wong, Z.S., Wang, L., Thanh, T.T., Van Nguyen, H. and Gilmour, S. (2021) Rapid Impact Assessments of COVID-19 Control Measures against the Delta Variant and Short-Term Projections of New Confirmed Cases in Vietnam. Journal of Global Health, 11, Article ID: 03118. https://doi.org/10.7189/jogh.11.03118
|
[52]
|
Nguyen, V.T. (2022) “ĐAI DICH COVID-19: Nguôn gôc Vi rut Gay Bẹnh, Vi rut Gay Bẹnh va Cac Biên Thê, Co Chê Gay Bẹnh, Hẹ Thông Phong Thu Miên Dich, Các Phån Úng Tư Kháng Đa Co'Quan Và Các Phuong Phaáp Điêu Tri” (COVID-19 Pandemic: Origin of the Viral Pathogen, Pathogenesis, Treatments…). The Vietnamese Journal of Medicine. (Presented at the Symposium For COVID-19 and Post-COVID Management, Hanoi, Vietnam April 22, 2022) (In Vietnamese)
|
[53]
|
Augusto, G., Mohsen, M.O., Zinkhan, S., Liu, X., Vogel, M. and Bachmann, M.F. (2022) In Vitro Data Suggest That Indian Delta Variant B.1.617 of SARS-CoV-2 Escapes Neutralization by Both Receptor Affinity and Immune Evasion. Allergy, 77, 111-117. https://doi.org/10.1111/all.15065
|
[54]
|
McCallum, M., Walls, A.C., Sprouse, K.R., Bowen, J.E., et al. (2021) Molecular Basis of Immune Evasion by the Delta and Kappa SARS-CoV-2 Variants. Science, 374, 1621-1626. https://doi.org/10.1126/science.abl8506
|
[55]
|
Zhang, J., Xiao, T., Cai, Y., Lavine, C.L., et al. (2021) Membrane Fusion and Immune Evasion by the Spike Protein of SARS-CoV-2 Delta Variant. Science (New York, N.Y.), 374, 1353-1360. https://doi.org/10.1126/science.abl9463
|
[56]
|
Mlcochova, P., Kemp, S.A., Dhar, M.S., Papa, G., et al. (2021) SARS-CoV-2 B.1.617.2 Delta Variant Replication and Immune Evasion. Nature, 599, 114-119. https://doi.org/10.1038/s41586-021-03944-y
|
[57]
|
Thorne, L.G., Bouhaddou, M., Reuschl, A.K., Zuliani-Alvarez, L., et al. (2022) Evolution of Enhanced Innate Immune Evasion by SARS-CoV-2. Nature, 602, 487-495. https://doi.org/10.1038/s41586-021-04352-y
|
[58]
|
Bast, E., Tang, F., Dahn, J. and Palacio, A. (2021) Increased Risk of Hospitalisation and Death with the Delta Variant in the USA. The Lancet: Infectious Diseases, 21, 1629-1630. https://doi.org/10.1016/S1473-3099(21)00685-X
|
[59]
|
Butt, A.A., Dargham, S.R., Chemaitelly, H., Al Khal, A., et al. (2022) Severity of Illness in Persons Infected with the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. JAMA Internal Medicine, 182, 197-205. https://doi.org/10.1001/jamainternmed.2021.7949
|
[60]
|
Ong, S., Chiew, C.J., Ang, L.W., Mak, T.M., et al. (2021) Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clinical Infectious Diseases, 75, e1128-e1136. https://doi.org/10.1093/cid/ciab721
|
[61]
|
Twohig, K.A., Nyberg, T., Zaidi, A., Thelwall, S., et al. and COVID-19 Genomics UK (COG-UK) Consortium (2022) Hospital Admission and Emergency Care Attendance Risk for SARS-CoV-2 Delta (B.1.617.2) Compared with Alpha (B.1.1.7) Variants of Concern: A Cohort Study. The Lancet: Infectious Diseases, 22, 35-42.
|
[62]
|
Ryu, B.H., Hong, S.I., Lim, S.J., Cho, Y., et al. (2021) Clinical Features of Adult COVID-19 Patients without Risk Factors before and after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-Variant Outbreak in Korea: Experience from Gyeongsangnam-Do. Journal of Korean Medical Science, 36, e341. https://doi.org/10.3346/jkms.2021.36.e341
|
[63]
|
Li, B., et al. (2022) Viral Infection and Transmission in a Large, Well-Traced Outbreak Caused by the SARS-CoV-2 Delta Variant. Nature Communications, 13, Article No. 460. https://doi.org/10.1038/s41467-022-28089-y
|
[64]
|
Teyssou, E., Delagrèverie, H., Visseaux, B., Lambert-Niclot, S., et al. (2021) The Delta SARS-CoV-2 Variant Has a Higher Viral Load than the Beta and the Historical Variants in Nasopharyngeal Samples from Newly Diagnosed COVID-19 Patients. The Journal of Infection, 83, e1-e3. https://doi.org/10.1016/j.jinf.2021.08.027
|
[65]
|
Mlcochova, P., Kemp, S.A., Dhar, M.S., Papa, G., et al. (2021) SARS-CoV-2 B.1.617.2 Delta Variant Replication and Immune Evasion. Nature, 599, 114-119. https://doi.org/10.1038/s41586-021-03944-y
|
[66]
|
Rodrigues, A.F., Soares, H.R., Guerreiro, M.R., Alves, P.M. and Coroadinha, A.S. (2015) Viral Vaccines and Their Manufacturing Cell Substrates: New Trends and Designs in Modern Vaccinology. Biotechnology Journal, 10, 1329-1344. https://doi.org/10.1002/biot.201400387
|
[67]
|
Hanley, K.A. (2011) The Double-Edged Sword: How Evolution Can Make or Break a Live-Attenuated Virus Vaccine. Evolution, 4, 635-643. https://doi.org/10.1007/s12052-011-0365-y
|
[68]
|
Kew, O.M., Sutter, R.W., de Gourville, E.M., Dowdle, W.R. and Pallansch, M.A. (2005) Vaccine-Derived Polioviruses and the Endgame Strategy for Global Polio Eradication. Annual Review of Microbiology, 59, 587-635. https://doi.org/10.1146/annurev.micro.58.030603.123625
|
[69]
|
Odoom, J.K., Yunus, Z., Dunn, G., Minor, P.D. and Martín, J. (2008) Changes in Population Dynamics during Long-Term Evolution of Sabin Type 1 Poliovirus in an Immunodeficient Patient. Journal of Virology, 82, 9179-9190. https://doi.org/10.1128/JVI.00468-08
|
[70]
|
Liu, Y., Yu, Y., Zhao, Y. and He, D. (January 16, 2022) Reduction in the Infection Fatality Rate of Omicron (B.1.1.529) Variant Compared to Previous Variants in South Africa. https://ssrn.com/abstract=4010080 https://doi.org/10.2139/ssrn.4010080
|
[71]
|
Viana, R., Moyo, S., Amoako, D.G., Tegally, H., et al. (2022) Rapid Epidemic Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa. Nature, 603, 679-686.
|
[72]
|
Wolter, N., Jassat, W., Walaza, S., Welch, R., et al. (2022) Early Assessment of the Clinical Severity of the SARS-CoV-2 Omicron Variant in South Africa: A Data Linkage Study. The Lancet, 399, 437-446. https://doi.org/10.1016/S0140-6736(22)00017-4
|
[73]
|
Abdullah, F., Myers, J., Basu, D., Tintinger, G., et al. (2022) Decreased Severity of Disease during the First Global Omicron Variant COVID-19 Outbreak in a Large Hospital in Tshwane, South Africa. International Journal of Infectious Diseases, 116, 38-42. https://doi.org/10.1016/j.ijid.2021.12.357
|
[74]
|
Jassat, W., Karim, S.A., Mudara, C., Welch, R., et al. (2021) Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa during the Omicron-Dominant Fourth Wave. DATCOV Author and Blumberg, Lucille and Cohen, Cheryl, Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave (December 29, 2021). https://doi.org/10.2139/ssrn.3996320
|
[75]
|
Davies, M.-A., Kassanjee, R., Rosseau, P., Morden, E., et al. (2022) Outcomes of Laboratory-Confirmed SARS-CoV-2 Infection in the Omicron-Driven Fourth Wave Compared with Previous Waves in the Western Cape Province, South Africa. Tropical Medicine & International Health, 27, 564-573. https://doi.org/10.1111/tmi.13752
|
[76]
|
Lewnard, J.A., Hong, V.X., et al. (2022) Clinical Outcomes among Patients Infected with Omicron (B.1.1.529) SARS-CoV-2 Variant in Southern California. medRxiv 2022.01.11.22269045.
|
[77]
|
Kim, M.K., Lee, B., Choi, Y.Y., Um, J., Lee, K.-S., et al. (2022) Clinical Characteristics of 40 Patients Infected with the SARS-CoV-2 Omicron Variant in Korea. Journal of Korean Medical Science, 37, e31. https://doi.org/10.3346/jkms.2022.37.e31
|
[78]
|
Lambrou, A.S., et al. (2022) Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants—United States, June 2021-January 2022. Morbidity and Mortality Weekly Report, 71, 206-211. https://doi.org/10.15585/mmwr.mm7106a4
|
[79]
|
The World Ometer. https://www.worldometers.info/coronavirus/
|
[80]
|
Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., et al. (2021) Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. The New England Journal of Medicine, 385, 1474-1484. https://doi.org/10.1056/NEJMoa2109072
|
[81]
|
Jung, J., Sung, H. and Kim, S.H. (2021) Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. The New England Journal of Medicine, 385, 1629-1630. https://doi.org/10.1056/NEJMc2113497
|
[82]
|
Amit, S., Gonen, T. and Regev-Yochay, G. (2021) Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. Reply. The New England Journal of Medicine, 385, 1630-1631. https://doi.org/10.1056/NEJMc2113497
|
[83]
|
Hahn, G., Lee, S., Prokopenko, D., et al. (2021) Unsupervised Genome-Wide Cluster Analysis: Nucleotide Sequences of the Omicron Variant of SARS-CoV-2 Are Similar to Sequences from Early 2020. bioRxiv 2021.12.29.474469. https://doi.org/10.1101/2021.12.29.474469
|
[84]
|
Bansal, K. and Kumar, S. (2022) Mutational Cascade of SARS-CoV-2 Leading to Evolution and Emergence of Omicron Variant. Virus Research, 315, Article ID: 198765. https://doi.org/10.1016/j.virusres.2022.198765
|
[85]
|
Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., et al. (2022) Considerable Escape of SARS-CoV-2 Omicron to Antibody Neutralization. Nature, 602, 671-675 https://doi.org/10.1038/d41586-021-03827-2
|
[86]
|
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., et al. (2021) Omicron-B.1.1.529 Leads to Widespread Escape from Neutralizing Antibody Responses. bioRxiv: The Preprint Server for Biology, 2021.12.03.471045.
|
[87]
|
Ikemura, N., Hoshino, A., Higuchi, Y., Taminishi, S., Inaba, T. and Matoba, S. (2021) SARS-CoV-2 Omicron Variant Escapes Neutralization by Vaccinated and Convalescent Sera and Therapeutic Monoclonal Antibodies. medRxiv 2021.12.13.21267761. https://doi.org/10.1101/2021.12.13.21267761
|
[88]
|
Rössler, A., Riepler, L., Bante, D., von Laer, D. and Kimpel, J. (2022) SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. The New England Journal of Medicine, 386, 698-700. https://doi.org/10.1056/NEJMc2119236
|
[89]
|
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., et al. (2021) The Omicron Variant Is Highly Resistant against Antibody-Mediated Neutralization: Implications for Control of the COVID-19 Pandemic. Cell, 185, 447-456.E11. https://doi.org/10.1101/2021.12.12.472286
|
[90]
|
Puhach, O., Adea, K., Hulo, N., Sattonnet, P., et al. (2022) Infectious Viral Load in Unvaccinated and Vaccinated Patients Infected with SARS-CoV-2 WT, Delta and Omicron. medRxiv 2022.01.10.22269010. https://doi.org/10.1101/2022.01.10.22269010
|
[91]
|
Golcuk, M., Yildiz, A. and Gur, M. (2022) Omicron BA.1 and BA.2 Variants Increase the Interactions of SARS-CoV-2 Spike Glycoprotein with ACE2. Journal of Molecular Graphics and Modelling, 117, Article ID: 108286. https://doi.org/10.1016/j.jmgm.2022.108286
|
[92]
|
Mannar, D., Saville, J.W., Zhu, X., Srivastava, S.S., et al. (2022) SARS-CoV-2 Omicron Variant: Antibody Evasion and Cryo-EM Structure of Spike Protein-ACE2 Complex. Science (New York, N.Y.), 375, 760-764. https://doi.org/10.1126/science.abn7760
|
[93]
|
Lamers, M.M., Mykytyn, A.Z., Breugem, T.I., Groen, N., et al. (2022) SARS-CoV-2 Omicron Efficiently Infects Human Airway, but Not Alveolar Epithelium. bioRxiv 2022.01.19.476898. https://doi.org/10.1101/2022.01.19.476898
|
[94]
|
Peacock, T.P., Brown, J.C., Zhou, J., Thakur, N., et al. (2021) The SARS-CoV-2 Variant, Omicron, Shows Rapid Replication in Human Primary Nasal Epithelial Cultures and Efficiently Uses the Endosomal Route of Entry. bioRxiv 2021.12.31.474653.
|
[95]
|
Nie, C., Sahoo, A.K., Herrmann, A., Ballauff, M., Netz, R.R. and Haag, R. (2022) Charge Matters: Mutations in Omicron Variant Favor Binding to Cells. ChemBioChem, 23, e202100681. https://doi.org/10.1002/cbic.202100681
|
[96]
|
Shuai, H., Chan, J.FW., Hu, B., et al. (2022) Attenuated Replication and Pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature, 603, 693-699. https://doi.org/10.1038/s41586-022-04442-5
|
[97]
|
McMahan, K., Giffin, V., Tostanoski, L.H., Chung, B., et al. (2022) Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. Clinical and Translational Report, 3, 262-268.E4. https://doi.org/10.1016/j.medj.2022.03.004
|
[98]
|
Abdelnabi, R., Foo, C.S., Zhang, X., Lemmens, V., et al. (2022) The Omicron (B.1.1.529) SARS-CoV-2 Variant of Concern Does Not Readily Infect Syrian Hamsters. Antiviral Research, 198, Article ID: 105253. https://doi.org/10.1016/j.antiviral.2022.105253
|
[99]
|
Halfmann, P.J., Iida, S., Iwatsuki-Horimoto, K., et al. (2022) SARS-CoV-2 Omicron Virus Causes Attenuated Disease in Mice and Hamsters. Nature, 603, 687-692. https://doi.org/10.1038/s41586-022-04441-6
|
[100]
|
Sato, K., Suzuki, R., Yamasoba, D., Kimura, I., Wang, L., Kishimoto, M., et al. (2022) Attenuated Fusogenicity and Pathogenicity of SARS-CoV-2 Omicron Variant. https://doi.org/10.21203/rs.3.rs-1207670/v1
|
[101]
|
Lewnard, J.A., Hong, V.X., Patel, M.M., Kahn, R., Lipsitch, M. and Tartof, S.Y. (2022) Clinical Outcomes among Patients Infected with Omicron (B.1.1.529) SARS-CoV-2 Variant in Southern California. medRxiv.
|
[102]
|
Khan, K., Karim, F., Cele, S., San, J.E., et al. (2022) Omicron Infection Enhances Delta Antibody Immunity in Vaccinated Persons. Nature, 607, 356-359. https://doi.org/10.1038/s41586-022-04830-x
|
[103]
|
Chan, L.S., Hammerberg, C. and Cooper, K.D. (1990) Cicatricial Pemphigoid. Identification of Two Distinct Sets of Epidermal Antigens by IgA and IgG Class Circulating Autoantibodies. Archives of Dermatology, 126, 1466-1468. https://doi.org/10.1001/archderm.1990.01670350080013
|
[104]
|
Chan, L.S., Fine, J.D., Briggaman, R.A., Woodley, D.T., Hammerberg, C., Drugge, R.J. and Cooper, K.D. (1993) Identification and Partial Characterization of a Novel 105-kDalton Lower Lamina Lucida Autoantigen Associated with a Novel Immune-Mediated Subepidermal Blistering Disease. The Journal of Investigative Dermatology, 101, 262-267.
|
[105]
|
Nguyen, V.T., Ndoye, A., Shultz, L.D., Pittelkow, M.R. and Grando, S.A. (2000) Antibodies against Keratinocyte Antigens Other than Desmogleins 1 and 3 Can Induce Pemphigus Vulgaris-Like Lesions. Journal of Clinical Investigation, 106, 1467-1479. https://doi.org/10.1172/JCI10305
|
[106]
|
Nguyen, V.T., Ndoye, A. and Grando, S.A. (2000) Pemphigus Vulgaris Antibody Identifies Pemphaxin. A Novel Keratinocyte Annexin-Like Molecule Binding Acetylcholine. Journal of Biological Chemistry, 275, 29466-29476. https://doi.org/10.1074/jbc.M003174200
|
[107]
|
Nguyen, V.T., Ndoye, A. and Grando, S.A. (2000) Novel Human Alpha9 Acetylcholine Receptor Regulating Keratinocyte Adhesion Is Targeted by Pemphigus Vulgaris Autoimmunity. The American Journal of Pathology, 157, 1377-1391. https://doi.org/10.1016/S0002-9440(10)64651-2
|
[108]
|
Kljuic, A., Bazzi, H., Sundberg, J.P., Panteleyev, A.A., Nguyen, V.T. and Christiano, A.M. (2003) Desmoglein 4 in Hair Follicle Differentiation and Epidermal Adhesion: Evidence from Inherited Hypotrichosis and Acquired Pemphigus Vulgaris. Cell, 113, 249-260. https://doi.org/10.1016/S0092-8674(03)00273-3
|
[109]
|
Nguyen, V.T. (2003) Chapter 19: Experimental Mouse Model of Pemphigus Vulgaris: Passive Transfer of Nondesmoglein 1 and 3 Antibodies. In: Chan, L.S., Ed., Animal Models of Human Inflammatory Skin Diseases, CRC Press LLC, Boca Raton, FL.
|
[110]
|
Nguyen, V.T., et al. (2001) Classification, Clinical Manifestations, and Immunopathological Mechanisms of the Epithelial Variant of Paraneoplastic Autoimmune Multiorgan Syndrome: A Reappraisal of Paraneoplastic Pemphigus. Archives of Dermatology, 137, 193-206.
|
[111]
|
Mendes, F.B., Hissa-Elian, A., Abreu, M.A. and Gonçalves, V.S. (2013) Review: Dermatitis Herpetiformis. Anais Brasileiros de Dermatologia, 88, 594-599. https://doi.org/10.1590/abd1806-4841.20131775
|
[112]
|
Nguyen, V.T., Kadunce, D.P., Hendrix, J.D., Gammon, W.R. and Zone, J.J. (1993) Inhibition of Neutrophil Adherence to Antibody by Dapsone: A Possible Therapeutic Mechanism of Dapsone in the Treatment of IgA Dermatoses. Journal of Investigative Dermatology, 100, 349-355. https://drive.google.com/file/d/1QqBjj9lVYVplqdEXjTrFYGrGyG25rqmp/view?usp=sharing https://doi.org/10.1111/1523-1747.ep12471811
|
[113]
|
Tsokos G.C. (2011) Systemic Lupus Erythematosus. The New England Journal of Medicine, 365, 2110-2121. https://doi.org/10.1056/NEJMra1100359
|
[114]
|
Clarindo, M.V., Possebon, A.T., Soligo, E.M., Uyeda, H., et al. (2014) Dermatitis Herpetiformis: Pathophysiology, Clinical Presentation, Diagnosis and Treatment. Anais Brasileiros de Dermatologia, 89, 865-877. https://doi.org/10.1590/abd1806-4841.20142966
|
[115]
|
Chorzelski, T.P., Beutner, E.H., Sulej, J., Tchorzewska, H., Jablonska, S., Kumar, V. and Kapuscinska, A. (1984) IgA Anti-Endomysium Antibody. A New Immunological Marker of Dermatitis Herpetiformis and Coeliac Disease. The British Journal of Dermatology, 111, 395-402. https://doi.org/10.1111/j.1365-2133.1984.tb06601.x
|
[116]
|
Mok, C.C. and Lau, C.S. (2003) Pathogenesis of Systemic Lupus Erythematosus. Journal of Clinical Pathology, 56, 481-490. https://doi.org/10.1136/jcp.56.7.481
|
[117]
|
Anhalt, G.J., Kim, S.C., Stanley, J.R., Korman, N.J., et al. (1990) Paraneoplastic Pemphigus. An Autoimmune Mucocutaneous Disease Associated with Neoplasia. The New England Journal of Medicine, 323, 1729-1735. https://doi.org/10.1056/NEJM199012203232503
|
[118]
|
Jackson, S.R., Koestenbauer, J., Carroll, A.P., Oo, T.H., Chou, S. and Indrajit, B. (2020) Paraneoplastic Bullous Pemphigoid—A Sign of Clear Cell Renal Carcinoma. Urology Case Reports, 30, Article ID: 101119. https://doi.org/10.1016/j.eucr.2020.101119
|
[119]
|
Pachinger, W. (1983) Zum paraneoplastischen Lichen ruber pemphigoides [Paraneoplastic Lichen Ruber Pemphigoides]. Zeitschrift fur Hautkrankheiten, 58, 1024-1037.
|
[120]
|
Smatti, M.K., Cyprian, F.S., Nasrallah, G.K., Al Thani, A.A., Almishal, R.O. and Yassine, H.M. (2019) Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses, 11, Article 762. https://doi.org/10.3390/v11080762
|
[121]
|
Kemppainen, K.M., Lynch, K.F., Liu, E., Lönnrot, M., et al. and TEDDY Study Group (2017) Factors That Increase Risk of Celiac Disease Autoimmunity after a Gastrointestinal Infection in Early Life. Clinical Gastroenterology and Hepatology, 15, 694-702.e5. https://doi.org/10.1016/j.cgh.2016.10.033
|
[122]
|
Blomqvist, M., Juhela, S., Erkkila, S., Korhonen, S., et al. (2002) Rotavirus Infections and Development of Diabetes-Associated Autoantibodies during the First 2 Years of life. Clinical and Experimental Immunology, 128, 511-515. https://doi.org/10.1046/j.1365-2249.2002.01842.x
|
[123]
|
Pane, J.A., Webster, N.L., Graham, K.L., Holloway, G., Zufferey, C. and Coulson, B.S. (2013) Rotavirus Acceleration of Murine Type 1 Diabetes Is Associated with a T Helper 1-Dependent Specific Serum Antibody Response and Virus Effects in Regional Lymph Nodes. Diabetologia, 56, 573-582. https://doi.org/10.1007/s00125-012-2798-4
|
[124]
|
Pak, C.Y., Eun, H.M., McArthur, R.G. and Yoon, J.W. (1988) Association of Cytomegalovirus Infection with Autoimmune Type 1 Diabetes. The Lancet (London, England), 332, 1-4. https://doi.org/10.1016/S0140-6736(88)92941-8
|
[125]
|
Laitinen, O.H., Honkanen, H., Pakkanen, O., Oikarinen, S., et al. (2014) Coxsackievirus B1 Is Associated with Induction of β-Cell Autoimmunity That Portends Type 1 Diabetes. Diabetes, 63, 446-455. https://doi.org/10.2337/db13-0619
|
[126]
|
Moon, U.Y., Park, S.J., Oh, S.T., Kim, W.U., et al. (2004) Patients with Systemic Lupus Erythematosus Have Abnormally Elevated Epstein-Barr Virus Load in Blood. Arthritis Research & Therapy, 6, R295-R302.
|
[127]
|
Draborg, A.H., Jørgensen, J.M., Müller, H., Nielsen, C.T., et al. (2012) Epstein-Barr Virus Early Antigen Diffuse (EBV-EA/D)-Directed Immunoglobulin A Antibodies in Systemic Lupus Erythematosus Patients. Scandinavian Journal of Rheumatology, 41, 280-289. https://doi.org/10.3109/03009742.2012.665944
|
[128]
|
Gross, A.J., Hochberg, D., Rand, W.M. and Thorley-Lawson, D.A. (2005) EBV and Systemic Lupus Erythematosus: A New Perspective. Journal of Immunology (Baltimore, MD.: 1950), 174, 6599-6607. https://doi.org/10.4049/jimmunol.174.11.6599
|
[129]
|
Bar-Or, A., Pender, M.P., Khanna, R., Steinman, L., et al. (2021) Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: (Trends in Molecular Medicine, 26:3 p:296-310, 2020). Trends in Molecular Medicine, 27, 410-411. https://doi.org/10.1016/j.molmed.2021.01.004
|
[130]
|
Price, J.V., et al. (2013) Protein Microarray Analysis Reveals BAFF-Binding Autoantibodies in Systemic Lupus Erythematosus. Journal of Clinical Investigation, 123, 5135-5145. https://doi.org/10.1172/JCI70231
|
[131]
|
Adler, B.L. and Christopher-Stine, L. (2018) Triggers of Inflammatory Myopathy: Insights into Pathogenesis. Discovery Medicine, 25, 75-83.
|
[132]
|
Girschick, H.J., Guilherme, L., Inman, R.D., Latsch, K., et al. (2008) Bacterial Triggers and Autoimmune Rheumatic Diseases. Clinical and Experimental Rheumatology, 26, S12-S17.
|
[133]
|
Seidel, M.F., Domene, A.B. and Vetter, H. (2007) Differential Diagnoses of Suspected Lyme Borreliosis or Post-Lyme-Disease Syndrome. European Journal of Clinical Microbiology & Infectious Diseases, 26, 611-617. https://doi.org/10.1007/s10096-007-0342-0
|
[134]
|
Yehudina, Y. and Trypilka, S. (2021) Lyme Borreliosis as a Trigger for Autoimmune Disease. Cureus, 13, e18648. https://doi.org/10.7759/cureus.18648
|
[135]
|
Tan, E.H., Sena, A.G., Prats-Uribe, A., You, S.C., et al. (2021) COVID-19 in Patients with Autoimmune Diseases: Characteristics and Outcomes in a Multinational Network of Cohorts across Three Countries. Rheumatology (Oxford), 60, SI37-SI50. https://doi.org/10.1093/rheumatology/keab250
|
[136]
|
Dreyer, N., Petruski-Ivleva, N., Albert, L., Mohamed, D., Brinkley, E., Reynolds, M. and Toovey, S. (2021) Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19. International Journal of General Medicine, 14, 3941-3949. https://doi.org/10.2147/IJGM.S313486
|
[137]
|
Akiyama, S., Hamdeh, S., Micic, D. and Sakuraba, A. (2021) Prevalence and Clinical Outcomes of COVID-19 in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis. Annals of the Rheumatic Diseases, 80, 384-391. https://doi.org/10.1136/annrheumdis-2020-218946
|
[138]
|
Chatterjee, B., Karandikar, R.L. and Mande, S.C. (2021) Mortality Due to COVID-19 in Different Countries Is Associated with Their Demographic Character and Prevalence of Autoimmunity. Current Science, 120, 501-508. https://doi.org/10.18520/cs/v120/i3/501-508
|
[139]
|
Gracia-Ramos, A.E., Martin-Nares, E., Hernández-Molina, G., et al. (2021) New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells, 10, Article 3592. https://doi.org/10.3390/cells10123592
|
[140]
|
Israeli, E., Agmon-Levin, N., Blank, M., Chapman, J. and Shoenfeld, Y. (2012) Guillain-Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or Vaccination. Clinical Reviews in Allergy & Immunology, 42, 121-130. https://doi.org/10.1007/s12016-010-8213-3
|
[141]
|
Toscano, G., et al. (2020) Guillain-Barré Syndrome Associated with SARS-CoV-2. The New England Journal of Medicine, 382, 2574-2576. https://doi.org/10.1056/NEJMc2009191
|
[142]
|
Newburger, J.W., Takahashi, M. and Burns, J.C. (2016) Kawasaki Disease. Journal of the American College of Cardiology, 67, 1738-1749. https://doi.org/10.1016/j.jacc.2015.12.073
|
[143]
|
Galeotti, C., Kaveri, S.V., Cimaz, R., Kon-Paut, I. and Bayry, J. (2016) Predisposing Factors, Pathogenesis, and Therapeutic Intervention of Kawasaki Disease. Drug Discovery Today, 21, 1850-1857. https://doi.org/10.1016/j.drudis.2016.08.004
|
[144]
|
Sakurai, Y. (2019) Autoimmune Aspects of Kawasaki Disease. Journal of Investigational Allergology & Clinical Immunology, 29, 251-261. https://doi.org/10.18176/jiaci.0300
|
[145]
|
Verdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri, M., Ciuffreda, M., Bonanomi, E. and D’Antiga, L. (2020) An Outbreak of Severe Kawasaki-Like Disease at the Italian Epicentre of the SARS-CoV-2 Epidemic: An Observational Cohort Study. The Lancet (London, England), 395, 1771-1778. https://doi.org/10.1016/S0140-6736(20)31103-X
|
[146]
|
Toubiana, J., Poirault, C., Corsia, A., Bajolle, F., et al. (2020) Kawasaki-Like multisystem Inflammatory Syndrome in Children during the Covid-19 Pandemic in Paris, France: Prospective Observational Study. BMJ, 369, m2094. https://doi.org/10.1136/bmj.m2094
|
[147]
|
Feldstein, L.R., Rose, E.B., Horwitz, S.M., Collins, J.P., et al. and CDC COVID-19 Response Team (2020) Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. The New England Journal of Medicine, 383, 334-346. https://doi.org/10.1056/NEJMoa2021680
|
[148]
|
Bautista-Rodriguez, C., Sanchez-de-Toledo, J., Clark, B.C., Herberg, J., et al. (2021) Multisystem Inflammatory Syndrome in Children: An International Survey. Pediatrics, 147, e2020024554. https://doi.org/10.1542/peds.2020-024554
|
[149]
|
Belhadjer, Z., Méot, M., Bajolle, F., Khraiche, D., et al. (2020) Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation, 142, 429-436. https://doi.org/10.1161/CIRCULATIONAHA.120.048360
|
[150]
|
Whittaker, E., Bamford, A., Kenny, J., Kaforou, et al. and PIMS-TS Study Group and EUCLIDS and PERFORM Consortia (2020) Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2. JAMA, 324, 259-269. https://doi.org/10.1001/jama.2020.10369
|
[151]
|
Tolunay, O., Çelik, Ü., Arslan, İ., Orgun, A., Demir, H., Demir, O. and Dağdelen, E.Ç. (2021) Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Case Series Experience in a Tertiary Care Hospital of Southern Turkey. Journal of Tropical Pediatrics, 67, fmab050. https://doi.org/10.1093/tropej/fmab050
|
[152]
|
Dufort, E.M., Koumans, E.H., Chow, E.J., Rosenthal, et al. and New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team (2020) Multisystem Inflammatory Syndrome in Children in New York State. The New England Journal of Medicine, 383, 347-358. https://doi.org/10.1056/NEJMoa2021756
|
[153]
|
McArdle, A.J., Vito, O., Patel, H., Seaby, E.G., et al. and BATS Consortium (2021) Treatment of Multisystem Inflammatory Syndrome in Children. The New England Journal of Medicine, 385, 11-22. https://doi.org/10.1056/NEJMoa2102968
|
[154]
|
Hoffmann, J. and Enk, A.H. (2019) High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease. Frontiers in Immunology, 10, Article 1090. https://doi.org/10.3389/fimmu.2019.01090
|
[155]
|
Consiglio, C.R., Cotugno, N., Sardh, F., Pou, C., et al. (2020) The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell, 183, 968-981.e7. https://doi.org/10.1016/j.cell.2020.09.016
|
[156]
|
Zhou, Y., Han, T., Chen, J., Hou, C., Jia, E., et al. (2020) Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clinical and Translational Science, 13, 1077-1086. https://doi.org/10.1111/cts.12805
|
[157]
|
Gagiannis, D., Steinestel, J., Hackenbroch, C., et al. (2020) COVID-19-Induced Acute Respiratory Failure—An Exacerbation of Organ-Specific Autoimmunity? medRxiv 2020.04.27.20077180. https://doi.org/10.1101/2020.04.27.20077180
|
[158]
|
Lerma, L.A., Chaudhary, A., Bryan, A., Morishima, C., Wener, M.H. and Fink, S.L. (2020) Prevalence of Autoantibody Responses in Acute Coronavirus Disease 2019 (COVID-19). Journal of Translational Autoimmunity, 3, Article ID: 100073. https://doi.org/10.1016/j.jtauto.2020.100073
|
[159]
|
Wang, E.Y., Mao, T., Klein, J., et al. (2021) Diverse Functional Autoantibodies in Patients with COVID-19. Nature, 595, 283-288. https://doi.org/10.1038/s41586-021-03631-y
|
[160]
|
Bastard, P., Rosen, L.B., Zhang, Q., et al. (2020) Autoantibodies against Type I IFNs in Patients with Life-Threatening COVID-19. Science, 370, eabd4585. https://doi.org/10.1126/science.abd4585
|
[161]
|
Solanich, X., Rigo-Bonnin, R., Gumucio, V.D., et al. (2021) Pre-Existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona. Journal of Clinical Immunology, 41, 1733-1744. https://doi.org/10.1007/s10875-021-01136-x
|
[162]
|
Troya, J., Bastard, P., Planas-Serra, L. et al. (2021) Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain. Journal of Clinical Immunology, 41, 914-922. https://doi.org/10.1007/s10875-021-01036-0
|
[163]
|
Tang, K.T., Hsu, B.C. and Chen, D.Y. (2021) Autoimmune and Rheumatic Manifestations Associated with COVID-19 in Adults: An Updated Systematic Review. Frontiers in Immunology, 12, Article ID: 645013. https://doi.org/10.3389/fimmu.2021.645013
|
[164]
|
Garg, M., Maralakunte, M., Garg, S., Dhooria, S., Sehgal, I., et al. (2021) The Conundrum of ‘Long-COVID-19’: A Narrative Review. International Journal of General Medicine, 14, 2491-2506. https://doi.org/10.2147/IJGM.S316708
|
[165]
|
Ramani, S.L., Samet, J., Franz, C.K., Hsieh, C., Nguyen, C.V., Horbinski, C. and Deshmukh, S. (2021) Musculoskeletal Involvement of COVID-19: Review of Imaging. Skeletal Radiology, 50, 1763-1773. https://doi.org/10.1007/s00256-021-03734-7
|
[166]
|
Ahmed, S., Zimba, O. and Gasparyan, A.Y. (2021) COVID-19 and the Clinical Course of Rheumatic Manifestations. Clinical Rheumatology, 40, 2611-2619. https://doi.org/10.1007/s10067-021-05691-x
|
[167]
|
Acosta-Ampudia, Y., Monsalve, D.M., Rojas, M., Rodríguez, Y., Zapata, E., Ramírez-Santana, C. and Anaya, J.M. (2022) Persistent Autoimmune Activation and Proinflammatory State in Post-COVID Syndrome. The Journal of Infectious Diseases, 225, 2155-2162. https://doi.org/10.1093/infdis/jiac017
|
[168]
|
Restivo, D.A., Centonze, D., Alesina, A. and Marchese-Ragona, R. (2020) Myasthenia Gravis Associated with SARS-CoV-2 Infection. Annals of Internal Medicine, 173, 1027-1028. https://doi.org/10.7326/L20-0845
|
[169]
|
Assini, A., Gandoglia, I., Damato, V., Rikani, K., Evoli, A. and Del Sette, M. (2021) Myasthenia Gravis Associated with Anti-MuSK Antibodies Developed after SARS-CoV-2 Infection. European Journal of Neurology, 28, 3537-3539. https://doi.org/10.1111/ene.14721
|
[170]
|
Zuniga, M., Gomes, C., Carsons, S.E., Bender, M.T., Cotzia, P., Miao, Q.R., Lee, D.C. and Rodriguez, A. (2021) Autoimmunity to Annexin A2 Predicts Mortality among Hospitalised COVID-19 Patients. The European Respiratory Journal, 58, Article ID: 2100918. https://doi.org/10.1183/13993003.00918-2021
|
[171]
|
Chang, S.E., Feng, A., Meng, W., Apostolidis, S.A., et al. (2021) New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19. Nature Communications, 12, Article No. 5417. https://doi.org/10.1038/s41467-021-25509-3
|
[172]
|
Aschman, T., Schneider, J., Greuel, S., Meinhardt, J., et al. (2021) Association between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died. JAMA Neurology, 78, 948-960. https://doi.org/10.1001/jamaneurol.2021.2004
|
[173]
|
Proal, A.D. and VanElzakker, M.B. (2021) Long COVID or Post-Acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Frontiers in Microbiology, 12, Article ID: 698169. https://doi.org/10.3389/fmicb.2021.698169
|
[174]
|
Huang, Y., Pinto, M.D., Borelli, J.L., Mehrabadi, M.A., et al. (2021) COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the Pandemic. medRxiv: The Preprint Server for Health Sciences, 2021.03.03.21252086. https://doi.org/10.1101/2021.03.03.21252086
|
[175]
|
Nalbandian, A., Sehgal, K., Gupta, A., et al. (2021) Post-Acute COVID-19 Syndrome. Nature Medicine, 27, 601-615. https://doi.org/10.1038/s41591-021-01283-z
|
[176]
|
Oran, D.P. and Topol, E.J. (2020) Prevalence of Asymptomatic SARS-CoV-2 Infection. Annals of Internal Medicine, 173, 362-367. https://doi.org/10.7326/M20-3012
|
[177]
|
Davies, N.G., Klepac, P., Liu, Y., et al. (2020) Age-Dependent Effects in the Transmission and Control of COVID-19 Epidemics. Nature Medicine, 26, 1205-1211. https://doi.org/10.1038/s41591-020-0962-9
|
[178]
|
Guan, W.J., Ni, Z.Y., Hu, Y., Zhong, N.S., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine, 382, 1708-1720. https://doi.org/10.1056/NEJMoa2002032
|
[179]
|
Jiang, F., Deng, L., Zhang, L., Cai, Y., et al. (2020) Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). Journal of General Internal Medicine, 35, 1545-1549. https://doi.org/10.1007/s11606-020-05762-w
|
[180]
|
de Roquetaillade, C., Bredin, S., Lascarrou, J.B., Soumagne, T., et al. (2021) Timing and Causes of Death in Severe COVID-19 Patients. Critical Care (London, England), 25, Article No. 224. https://doi.org/10.1186/s13054-021-03639-w
|
[181]
|
Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., et al. (2020) Estimates of the Severity of Coronavirus Disease 2019: A Model-Based Analysis. The Lancet: Infectious Diseases, 20, 669-677. https://doi.org/10.1016/S1473-3099(20)30243-7
|
[182]
|
Woolf, S.H., Chapman, D.A. and Lee, J.H. (2021) COVID-19 as the Leading Cause of Death in the United States. JAMA, 325, 123-124. https://doi.org/10.1001/jama.2020.24865
|
[183]
|
Folgueira, M.D., et al. (2021) Prolonged SARS-CoV-2 Cell Culture Replication in Respiratory Samples from Patients with Severe COVID-19. Clinical Microbiology and Infection, 27, 886-891. https://doi.org/10.1016/j.cmi.2021.02.014
|
[184]
|
Prebensen, C., et al. (2021) Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Plasma Is Associated with Intensive Care Unit Admission and Mortality in Patients Hospitalized with Coronavirus Disease 2019. Clinical Infectious Diseases, 73, e799-e802. https://doi.org/10.1093/cid/ciaa1338
|
[185]
|
Li, Y., Schneider, A.M., Mehta, A., et al. (2021) SARS-CoV-2 Viremia Is Associated with Distinct Proteomic Pathways and Predicts COVID-19 Outcomes. Journal of Clinical Investigation, 131, e148635. https://doi.org/10.1172/JCI148635
|
[186]
|
Fajnzylber, J., et al. (2020) Massachusetts Consortium for Pathogen Readiness. SARS-CoV-2 Viral Load Is Associated with Increased Disease Severity and Mortality. Nature Communications, 11, Article No. 5493. https://doi.org/10.1038/s41467-020-19057-5
|
[187]
|
Matsuishi, Y., Mathis, B.J., Shimojo, N., Subrina, J., Okubo, N. and Inoue, Y. (2021) Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions. Biomedicines, 9, Article 279. https://doi.org/10.3390/biomedicines9030279
|
[188]
|
Chen, T., Wu, D., Chen, H., Yan, W., et al. (2020) Clinical Characteristics of 113 Deceased Patients with Coronavirus Disease 2019: Retrospective Study. BMJ, 368, m1091. https://doi.org/10.1136/bmj.m1091
|
[189]
|
Katz, L.M. (2020) Is SARS-CoV-2 Transfusion Transmitted? Transfusion, 60, 1111-1114. https://doi.org/10.1111/trf.15831
|
[190]
|
Andersson, M.I., et al. (2020) SARS-CoV-2 RNA Detected in Blood Products from Patients with COVID-19 Is Not Associated with Infectious Virus. Wellcome Open Research, 5, 181. https://doi.org/10.12688/wellcomeopenres.16002.2
|
[191]
|
Diao, B., Wang, C., Wang, R., Feng, Z., et al. (2021) Human Kidney Is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Nature Communications, 12, Article No. 2506. https://doi.org/10.1038/s41467-021-22781-1
|
[192]
|
Argyropoulos, K.V., Serrano, A., Hu, J., Black, M., et al. (2020) Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms. The American Journal of Pathology, 190, 1881-1887. https://doi.org/10.1016/j.ajpath.2020.07.001
|
[193]
|
Verity, R., Okell, L C., Dorigatti, I., Winskill, P., et al. (2020) Estimates of the Severity of Coronavirus Disease 2019: A Model-Based Analysis. The Lancet: Infectious Diseases, 20, 669-677. https://doi.org/10.1016/S1473-3099(20)30243-7
|
[194]
|
Elezkurtaj, S., Greuel, S., Ihlow, J., Michaelis, E.G., et al. (2021) Causes of Death and Comorbidities in Hospitalized Patients with COVID-19. Scientific Reports, 11, Article No. 4263. https://doi.org/10.1038/s41598-021-82862-5
|
[195]
|
Wichmann, D., Sperhake, J.P., Lütgehetmann, M., Steurer, S., et al. (2020) Autopsy Findings and Venous Thromboembolism in Patients with COVID-19: A Prospective Cohort Study. Annals of Internal Medicine, 173, 268-277. https://doi.org/10.7326/M20-2003
|
[196]
|
Fox, S.E., Akmatbekov, A., Harbert, J.L., Li, G., Quincy Brown, J. and Vander Heide, R.S. (2020) Pulmonary and Cardiac Pathology in African American Patients with COVID-19: An Autopsy Series from New Orleans. The Lancet: Respiratory Medicine, 8, 681-686. https://doi.org/10.1016/S2213-2600(20)30243-5
|
[197]
|
Haberecker, M., Schwarz, E.I., Steiger, P., Frontzek, K., et al. (2022) Autopsy-Based Pulmonary and Vascular Pathology: Pulmonary Endotheliitis and Multi-Organ Involvement in COVID-19 Associated Deaths. Respiration, 101, 155-165. https://doi.org/10.1159/000518914
|
[198]
|
Fitzek, A., Schädler, J., Dietz, E., Ron, A., et al. (2021) Prospective Postmortem Evaluation of 735 Consecutive SARS-CoV-2-Associated Death Cases. Scientific Reports, 11, Article No. 19342. https://doi.org/10.1038/s41598-021-98499-3
|
[199]
|
Borczuk, A.C., Salvatore, S.P., Seshan, S.V., Patel, S.S., et al. (2020) COVID-19 Pulmonary Pathology: A Multi-Institutional Autopsy Cohort from Italy and New York City. Modern Pathology, 33, 2156-2168. https://doi.org/10.1038/s41379-020-00661-1
|
[200]
|
Mayadas, T.N., Cullere, X. and Lowell, C.A. (2014) The Multifaceted Functions of Neutrophils. Annual Review of Pathology, 9, 181-218. https://doi.org/10.1146/annurev-pathol-020712-164023
|
[201]
|
Korkmaz, B., Horwitz, M.S., Jenne, D.E. and Gauthier, F. (2010) Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases. Pharmacological Reviews, 62, 726-759. https://doi.org/10.1124/pr.110.002733
|
[202]
|
Cicco, S., Cicco, G., Racanelli, V. and Vacca, A. (2020) Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. Mediators of Inflammation, 2020, Article ID: 7527953. https://doi.org/10.1155/2020/7527953
|
[203]
|
Bucurenci, N., Blake, D.R., Chidwick, K. and Winyard, P.G. (1992) Inhibition of Neutrophil Superoxide Production by Human Plasma Alpha 1-Antitrypsin. FEBS Letters, 300, 21-24. https://doi.org/10.1016/0014-5793(92)80156-B
|
[204]
|
Hurley, K., Lacey, N., O’Dwyer, C.A., Bergin, D.A., et al. (2014) Alpha-1 Antitrypsin Augmentation Therapy Corrects Accelerated Neutrophil Apoptosis in Deficient Individuals. The Journal of Immunology, 193, 3978-3991. https://doi.org/10.4049/jimmunol.1400132
|
[205]
|
Bergin, D.A., et al. (2010) α-1 Antitrypsin Regulates Human Neutrophil Chemotaxis Induced by Soluble Immune Complexes and IL-8. Journal of Clinical Investigation, 120, 4236-4250. https://doi.org/10.1172/JCI41196
|
[206]
|
Bergin, D.A., et al. (2014) The Circulating Proteinase Inhibitor α-1 Antitrypsin Regulates Neutrophil Degranulation and Autoimmunity. Science Translational Medicine, 6, 217ra1. https://doi.org/10.1126/scitranslmed.3007116
|
[207]
|
Sun, S., et al. (2020) Abnormalities of Peripheral Blood System in Patients with COVID-19 in Wenzhou, China. Clinica Chimica Acta, 507, 174-180. https://doi.org/10.1016/j.cca.2020.04.024
|
[208]
|
Liu, J., et al. (2020) Longitudinal Characteristics of Lymphocyte Responses and Cytokine Profiles in the Peripheral Blood of SARS-CoV-2 Infected Patients. eBioMedicine, 55, Article ID: 102763. https://doi.org/10.1016/j.ebiom.2020.102763
|
[209]
|
Kong, M., Zhang, H., Cao, X., Mao, X. and Lu, Z. (2020) Higher Level of Neutrophil-to-Lymphocyte Is Associated with Severe COVID-19. Epidemiology & Infection, 148, e139. https://doi.org/10.1017/S0950268820001557
|
[210]
|
Pakos, I.S., et al. (2020) Characteristics of Peripheral Blood Differential Counts in Hospitalized Patients with COVID-19. European Journal of Haematology, 105, 773-778. https://doi.org/10.1111/ejh.13509
|
[211]
|
Vafadar Moradi, E., Teimouri, A., Rezaee, R., Morovatdar, N., et al. (2020) Increased Age, Neutrophil-to-Lymphocyte Ratio (NLR) and White Blood Cells Count Are Associated with Higher COVID-19 Mortality. The American Journal of Emergency Medicine, 40, 11-14. https://doi.org/10.1016/j.ajem.2020.12.003
|
[212]
|
Wu, P., et al. (2021) The Trans-Omics Landscape of COVID-19. Nature Communications, 12, Article No. 4543. https://doi.org/10.1038/s41467-021-24482-1
|
[213]
|
Ackermann, M., Anders, H.J., Bilyy, R., Bowlin, G.L., et al. (2021) Patients with COVID-19: In the Dark-NETs of Neutrophils. Cell Death and Differentiation, 28, 3125-3139. https://doi.org/10.1038/s41418-021-00805-z
|
[214]
|
Hammad, R., et al. (2021) Circulating Cell-Free DNA, Peripheral Lymphocyte Subsets Alterations and Neutrophil Lymphocyte Ratio in Assessment of COVID-19 Severity. Innate Immunity, 27, 240-250. https://doi.org/10.1177/1753425921995577
|
[215]
|
McElvaney, O.J., et al. (2020) Characterization of the Inflammatory Response to Severe COVID-19 Illness. American Journal of Respiratory and Critical Care Medicine, 202, 812-821. https://doi.org/10.1164/rccm.202005-1583OC
|
[216]
|
Chen, H., Liu, W., Wang, Y., Liu, D., Zhao, L. and Yu, J. (2021) SARS-CoV-2 Activates Lung Epithelial Cell Proinflammatory Signaling and Leads to Immune Dysregulation in COVID-19 Patients. eBioMedicine, 70, Article ID: 103500. https://doi.org/10.1016/j.ebiom.2021.103500
|
[217]
|
Tomar, B., Anders, H.J., Desai, J. and Mulay, S.R. (2020) Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19. Cells, 9, Article 1383. https://doi.org/10.3390/cells9061383
|
[218]
|
Zuo, Y., Yalavarthi, S., Navaz, S.A., Hoy, C.K., et al. (2021) Autoantibodies Stabilize Neutrophil Extracellular Traps in COVID-19. JCI Insight, 6, e150111. https://doi.org/10.1172/jci.insight.150111
|
[219]
|
Wang, J., Li, Q., Yin, Y., Zhang, Y., et al. (2020) Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19. Frontiers in Immunology, 11, Article 2063. https://doi.org/10.3389/fimmu.2020.02063
|
[220]
|
Yang, J., Wu, Z., Long, Q., Huang, J., Hong, T., Liu, W. and Lin, J. (2020) Insights into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13. Frontiers in Immunology, 11, Article 610696. https://doi.org/10.3389/fimmu.2020.610696
|
[221]
|
Reusch, N., De Domenico, E., Bonaguro, L., Schulte-Schrepping, J., Baßler, K., Schultze, J.L. and Aschenbrenner, A.C. (2021) Neutrophils in COVID-19. Frontiers in Immunology, 12, Article ID: 652470. https://doi.org/10.3389/fimmu.2021.652470
|
[222]
|
Rothan, H.A. and Byrareddy, S.N. (2020) The Epidemiology and Pathogenesis of Coronavirus Disease (COVID-19) Outbreak. Journal of Autoimmunity, 109, Article ID: 102433. https://doi.org/10.1016/j.jaut.2020.102433
|
[223]
|
Middleton, E.A., He, X.Y., Denorme, F., et al. (2020) Neutrophil Extracellular Traps Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome. Blood, 136, 1169-1179. https://doi.org/10.1182/blood.2020007008
|
[224]
|
Blasco, A., Coronado, M.J., Hernández-Terciado, F., Martín, P., et al. (2021) Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients with COVID-19 and Myocardial Infarction. JAMA Cardiology, 6, 469-474. https://doi.org/10.1001/jamacardio.2020.7308
|
[225]
|
Veras, F.P., Pontelli, M.C., Silva, C.M., et al. (2020) SARS-CoV-2-Triggered Neutrophil Extracellular Traps Mediate COVID-19 Pathology. The Journal of Experimental Medicine, 217, e20201129. https://doi.org/10.1084/jem.20201129
|
[226]
|
Janiuk, K., Jabłońska, E. and Garley, M. (2021) Significance of NETs Formation in COVID-19. Cells, 10, Article 151. https://doi.org/10.3390/cells10010151
|
[227]
|
Tagami, T., Tosa, R., Omura, M., Fukushima, H., et al. (2014) Effect of a Selective Neutrophil Elastase Inhibitor on Mortality and Ventilator-Free Days in Patients with Increased Extravascular Lung Water: A Post Hoc Analysis of the PiCCO Pulmonary Edema Study. Journal of Intensive Care, 2, Article No. 67. https://doi.org/10.1186/s40560-014-0067-y
|
[228]
|
Barnes, B.J., Adrover, J.M., Baxter-Stoltzfus, A., et al. (2020) Targeting Potential Drivers of COVID-19: Neutrophil Extracellular Traps. The Journal of Experimental Medicine, 217, e20200652. https://doi.org/10.1084/jem.20200652
|
[229]
|
Al-Kuraishy, H.M., Al-Gareeb, A.I., Al-Hussaniy, H.A., Al-Harcan, N.A.H., Alexiou, A. and Batiha, G.E. (2022) Neutrophil Extracellular Traps (NETs) and Covid-19: A New Frontiers for Therapeutic Modality. International Immunopharmacology, 104, Article ID: 108516. https://doi.org/10.1016/j.intimp.2021.108516
|
[230]
|
Strich, J.R., Ramos-Benitez, M.J., Randazzo, D., Stein, S.R., et al. (2021) Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. The Journal of Infectious Diseases, 223, 981-984. https://doi.org/10.1093/infdis/jiaa789
|
[231]
|
Fajgenbaum, D.C. and June, C.H. (2020) Cytokine Storm. The New England Journal of Medicine, 383, 2255-2273. https://doi.org/10.1056/NEJMra2026131
|
[232]
|
Huang, C., Wang, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
|
[233]
|
Notz, Q., Schmalzing, M., Wedekink, F., Schlesinger, T., et al. (2020) Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. Frontiers in Immunology, 11, Article ID: 581338. https://doi.org/10.3389/fimmu.2020.581338
|
[234]
|
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J. and Wen, C. (2020) Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Frontiers in Immunology, 11, Article 1708. https://doi.org/10.3389/fimmu.2020.01708
|
[235]
|
Yang, L., Xie, X., Tu, Z., et al. (2021) The Signal Pathways and Treatment of Cytokine Storm in COVID-19. Signal Transduction and Targeted Therapy, 6, Article No. 255. https://doi.org/10.1038/s41392-021-00679-0
|
[236]
|
Stockman, L.J., Bellamy, R. and Garner, P. (2006) SARS: Systematic Review of Treatment Effects. PLOS Medicine, 3, e343. https://doi.org/10.1371/journal.pmed.0030343
|
[237]
|
Arabi, Y.M., Mandourah, Y., Al-Hameed, F., et al. (2018) Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. American Journal of Respiratory and Critical Care Medicine, 197, 757-767. https://doi.org/10.1164/rccm.201706-1172OC
|
[238]
|
Brattsand, R. and Linden, M. (1996) Cytokine Modulation by Glucocorticoids: Mechanisms and Actions in Cellular Studies. Alimentary Pharmacology & Therapeutics, 10, 81-92. https://doi.org/10.1046/j.1365-2036.1996.22164025.x
|
[239]
|
Nguyen, V.T., Arredondo, J., Chernyavsky, A.I., Kitajima, Y., Pittelkow, M. and Grando, S.A. (2004) Pemphigus Vulgaris IgG and Methylprednisolone Exhibit Reciprocal Effects on Keratinocytes. Journal of Biological Chemistry, 279, 2135-2146. https://doi.org/10.1074/jbc.M309000200
|
[240]
|
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al. (2021) Association between Administration of IL-6 Antagonists and Mortality among Patients Hospitalized for COVID-19: A Meta-Analysis. JAMA, 326, 499-518.
|
[241]
|
Woo, P.C., Lau, S.K., Wong, B.H., Chan, K.H., et al. (2004) Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS Coronavirus. Clinical and Diagnostic Laboratory Immunology, 11, 665-668. https://doi.org/10.1128/CDLI.11.4.665-668.2004
|
[242]
|
Hsueh, P.R., Huang, L.M., Chen, P.J., Kao, C.L. and Yang, P.C. (2004) Chronological Evolution of IgM, IgA, IgG and Neutralisation Antibodies after Infection with SARS-Associated Coronavirus. Clinical Microbiology and Infection, 10, 1062-1066. https://doi.org/10.1111/j.1469-0691.2004.01009.x
|
[243]
|
van de Sandt, C.E., Kreijtz, J.H. and Rimmelzwaan, G.F. (2012) Evasion of Influenza A Viruses from Innate and Adaptive Immune Responses. Viruses, 4, 1438-1476. https://doi.org/10.3390/v4091438
|
[244]
|
Ko, J.H., Müller, M.A., Seok, H., Park, G.E., et al. (2017) Suggested New Breakpoints of Anti-MERS-CoV Antibody ELISA Titers: Performance Analysis of Serologic Tests. European Journal of Clinical Microbiology & Infectious Diseases, 36, 2179-2186. https://doi.org/10.1007/s10096-017-3043-3
|
[245]
|
Padoan, A., Sciacovelli, L., Basso, D., Negrini, D., et al. (2020) IgA-Ab Response to Spike Glycoprotein of SARS-CoV-2 in Patients with COVID-19: A Longitudinal Study. Clinica Chimica Acta, 507, 164-166. https://doi.org/10.1016/j.cca.2020.04.026
|
[246]
|
Yu, H.Q., Sun, B.Q., Fang, Z.F., Zhao, J.C., et al. (2020) Distinct Features of SARS-CoV-2-Specific IgA Response in COVID-19 Patients. European Respiratory Journal, 56, Article ID: 2001526. https://doi.org/10.1183/13993003.01526-2020
|
[247]
|
Ma, H., Zeng, W., He, H., Zhao, D., et al. (2020) Serum IgA, IgM, and IgG Responses in COVID-19. Cellular & Molecular Immunology, 17, 773-775. https://doi.org/10.1038/s41423-020-0474-z
|
[248]
|
Barzegar-Amini, M., Mahmoudi, M., Dadgarmoghaddam, M., Farzad, F., Najafabadi, A.Q. and Jabbari-Azad, F. (2022) Comparison of Serum Total IgA Levels in Severe and Mild COVID-19 Patients and Control Group. Journal of Clinical Immunology, 42, 10-18. https://doi.org/10.1007/s10875-021-01149-6
|
[249]
|
Zervou, F.N., Louie, P., Stachel, A., Zacharioudakis, I.M., Ortiz-Mendez, Y., Thomas, K. and Aguero-Rosenfeld, M.E. (2021) SARS-CoV-2 Antibodies: IgA Correlates with Severity of Disease in Early COVID-19 Infection. Journal of Medical Virology, 93, 5409-5415. https://doi.org/10.1002/jmv.27058
|
[250]
|
Sugino, H., Sawada, Y. and Nakamura, M. (2021) IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes. International Journal of Molecular Sciences, 22, Article 7538. https://doi.org/10.3390/ijms22147538
|
[251]
|
Suso, A.S., Mon, C., Oñate Alonso, I., Galindo Romo, K., et al. (2020) IgA Vasculitis with Nephritis (Henoch-Schönlein Purpura) in a COVID-19 Patient. Kidney International Reports, 5, 2074-2078. https://doi.org/10.1016/j.ekir.2020.08.016
|
[252]
|
AlGhoozi, D.A. and AlKhayyat, H.M. (2021) A Child with Henoch-Schonlein Purpura Secondary to a COVID-19 Infection. BMJ Case Reports, 14, e239910. https://doi.org/10.1136/bcr-2020-239910
|
[253]
|
Hoskins, B., Keeven, N., Dang, M., Keller, E. and Nagpal, R. (2021) A Child with COVID-19 and Immunoglobulin A Vasculitis. Pediatric Annals, 50, e44-e48. https://doi.org/10.3928/19382359-20201211-01
|
[254]
|
Allez, M., Denis, B., Bouaziz, J.D., Battistella, M., et al. (2020) COVID-19-Related IgA Vasculitis. Arthritis & Rheumatology (Hoboken, N.J.), 72, 1952-1953. https://doi.org/10.1002/art.41428
|
[255]
|
Jacobi, M., Lancrei, H.M., Brosh-Nissimov, T. and Yeshayahu, Y. (2021) Purpurona: A Novel Report of COVID-19-Related Henoch-Schonlein Purpura in a Child. The Pediatric Infectious Disease Journal, 40, e93-e94. https://doi.org/10.1097/INF.0000000000003001
|
[256]
|
Sandhu, S., Chand, S., Bhatnagar, A., Dabas, R., Bhat, S., Kumar, H. and Dixit, P.K. (2021) Possible Association between IgA Vasculitis and COVID-19. Dermatologic Therapy, 34, e14551. https://doi.org/10.1111/dth.14551
|
[257]
|
Li, N.L., Papini, A.B., Shao, T. and Girard, L. (2021) Immunoglobulin-A Vasculitis with Renal Involvement in a Patient with COVID-19: A Case Report and Review of Acute Kidney Injury Related to SARS-CoV-2. Canadian Journal of Kidney Health and Disease, 8. https://doi.org/10.1177/2054358121991684
|
[258]
|
Zhang, Z., Zhang, G., Guo, M., Tao, W., Liu, X., Wei, H., Jin, T., Zhang, Y. and Zhu, S. (2021) The Potential Role of an Aberrant Mucosal Immune Response to SARS-CoV-2 in the Pathogenesis of IgA Nephropathy. Pathogens, 10, Article 881. https://doi.org/10.3390/pathogens10070881
|
[259]
|
Barbetta, L., Filocamo, G., Passoni, E., Boggio, F., Folli, C. and Monzani, V. (2021) Henoch-Schönlein Purpura with Renal and Gastrointestinal Involvement in Course of COVID-19: A Case Report. Clinical and Experimental Rheumatology, 39, 191-192. https://doi.org/10.55563/clinexprheumatol/5epvob
|
[260]
|
Jedlowski, P.M. and Jedlowski, M.F. (2022) Coronavirus Disease 2019-Associated Immunoglobulin A Vasculitis/Henoch-Schönlein Purpura: A Case Report and Review. The Journal of Dermatology, 49, 190-196. https://doi.org/10.1111/1346-8138.16211
|
[261]
|
Guney, C. and Akar, F. (2021) Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes. Journal of Pharmacy & Pharmaceutical Sciences, 24, 84-93. https://doi.org/10.18433/jpps31455
|
[262]
|
Zuo, Y., Estes, S.K., Ali, R.A., Gandhi, A.A., et al. (2020) Prothrombotic Autoantibodies in Serum from Patients Hospitalized with COVID-19. Science Translational Medicine, 12, eabd3876. https://doi.org/10.1126/scitranslmed.abd3876
|
[263]
|
Hasan Ali, O., Bomze, D., Risch, L., Brugger, S.D., et al. (2021) Severe Coronavirus Disease 2019 (COVID-19) Is Associated with Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clinical Infectious Diseases, 73, e2869-e2874. https://doi.org/10.1093/cid/ciaa1496
|
[264]
|
Hou, Y.J., Okuda, K., Edwards, C.E., Martinez, D.R., et al. (2020) SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell, 182, 429-446.E14. https://doi.org/10.1016/j.cell.2020.05.042
|
[265]
|
Sterlin, D., Mathian, A., Miyara, M., Mohr, A., et al. (2021) IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2. Science Translational Medicine, 13, eabd2223. https://doi.org/10.1126/scitranslmed.abd2223
|
[266]
|
Zone, J.J. (1991) Dermatitis Herpetiformis. Current Problems in Dermatology, 3, 6-41. https://doi.org/10.1016/1040-0486(91)90003-M
|
[267]
|
Diaz, M.S., Morita, L., Ferrari, B., Sartori, S., Greco, M.F., Sobrevias Bonells, L., et al. (2019) Linear IgA Bullous Dermatosis: A Series of 17 Cases. Actas Dermo- Sifiliográficas, 110, 673-680. https://doi.org/10.1016/j.ad.2018.06.017
|
[268]
|
Wang, J., Kwon, J., Ding, X., Fairley, J.A., Woodley, D.T. and Chan, L.S. (1997) Nonsecretory IgA1 Autoantibodies Targeting Desmosomal Component Desmoglein 3 in Intraepidermal Neutrophilic IgA Dermatosis. The American Journal of Pathology, 150, 1901-1907.
|
[269]
|
Hendrix, J.D., Mangum, K.L., Zone, J.J. and Gammon, W.R. (1990) Cutaneous IgA Deposits in Bullous Diseases Function as Ligands to Mediate Adherence of Activated Neutrophils. Journal of Investigative Dermatology, 94, 667-672. https://doi.org/10.1111/1523-1747.ep12876246
|
[270]
|
Dieterich, W., Laag, E., Bruckner-Tuderman, L., Reunala, T., Schuppan, D., et al. (1999) Antibodies to Tissue Transglutaminase as Serologic Markers in Patients with Dermatitis Herpetiformis. The Journal of Investigative Dermatology, 113, 133-136. https://doi.org/10.1046/j.1523-1747.1999.00627.x
|
[271]
|
Lingel, H., Meltendorf, S., Billing, U., Thurm, C., et al. (2021) Unique Autoantibody Prevalence in Long-Term Recovered SARS-CoV-2-Infected Individuals. Journal of Autoimmunity, 122, Article ID: 102682. https://doi.org/10.1016/j.jaut.2021.102682
|
[272]
|
Penumatsa, K.C., Toksoz, D., Warburton, R.R., Kharnaf, M., et al. (2017) Transglutaminase 2 in Pulmonary and Cardiac Tissue Remodeling in Experimental Pulmonary Hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology, 313, L752-L762. https://doi.org/10.1152/ajplung.00170.2017
|
[273]
|
Mokhtari, T., Hassani, F., Ghaffari, N., Ebrahimi, B., Yarahmadi, A. and Hassanzadeh, G. (2020) COVID-19 and Multiorgan Failure: A Narrative Review on Potential Mechanisms. Journal of Molecular Histology, 51, 613-628. https://doi.org/10.1007/s10735-020-09915-3
|
[274]
|
Ronchetti, S., Ayroldi, E., Ricci, E., Gentili, M., Migliorati, G. and Riccardi, C. (2021) A Glance at the Use of Glucocorticoids in Rare Inflammatory and Autoimmune Diseases: Still an Indispensable Pharmacological Tool? Frontiers in Immunology, 11, Article ID: 613435. https://doi.org/10.3389/fimmu.2020.613435
|
[275]
|
Flammer, J.R. and Rogatsky, I. (2011) Minireview: Glucocorticoids in Autoimmunity: Unexpected Targets and Mechanisms. Molecular Endocrinology (Baltimore, MD), 25, 1075-1086. https://doi.org/10.1210/me.2011-0068
|
[276]
|
Ni, Y.-N., Chen, G., Sun, J., Liang, B.-M. and Liang, Z.-A. (2019) The Effect of Corticosteroids on Mortality of Patients with Influenza Pneumonia: A Systematic Review and Meta-Analysis. Critical Care, 23, Article No. 99. https://doi.org/10.1186/s13054-019-2395-8
|
[277]
|
Zhou, Y., Fu, X., Liu, X., et al. (2020) Use of Corticosteroids in Influenza-Associated Acute Respiratory Distress Syndrome and Severe Pneumonia: A Systemic Review and Meta-Analysis. Scientific Reports, 10, Article No. 3044. https://doi.org/10.1038/s41598-020-59732-7
|
[278]
|
RECOVERY Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., et al. (2021) Dexamethasone in Hospitalized Patients with Covid-19. The New England Journal of Medicine, 384, 693-704. https://doi.org/10.1056/NEJMoa2021436
|
[279]
|
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al. (2020) Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-Analysis. JAMA, 324, 1330-1341. https://doi.org/10.1001/jama.2020.17023
|
[280]
|
Wang, Y., Jiang, W., He, Q., Wang, C., et al. (2020) A Retrospective Cohort Study of Methylprednisolone Therapy in Severe Patients with COVID-19 Pneumonia. Signal Transduction and Targeted Therapy, 5, Article No. 57. https://doi.org/10.1038/s41392-020-0158-2
|
[281]
|
Papamanoli, A., Yoo, J., Grewal, P., Predun, W., Hotelling, J., et al. (2021) High-Dose Methylprednisolone in Nonintubated Patients with Severe COVID-19 Pneumonia. European Journal of Clinical Investigation, 51, e13458. https://doi.org/10.1111/eci.13458
|
[282]
|
Edalatifard, M., et al. (2020) Intravenous Methylprednisolone Pulse as a Treatment for Hospitalised Severe COVID-19 Patients: Results from a Randomised Controlled Clinical Trial. European Respiratory Journal, 56, Article ID: 2002808. https://doi.org/10.1183/13993003.02808-2020
|
[283]
|
Salton, F., et al. (2020) Prolonged Low-Dose Methylprednisolone in Patients with Severe COVID-19 Pneumonia. Open Forum Infectious Diseases, 7, ofaa421. https://doi.org/10.1093/ofid/ofaa421
|
[284]
|
Fernández-Cruz, A., Ruiz-Antorán, B., Muñoz-Gómez, A., Sancho-López, A., et al. (2020) Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. Antimicrobial Agents and Chemo-therapy, 64, e01168-20. https://doi.org/10.1128/AAC.01168-20
|
[285]
|
Chaudhuri, D., Sasaki, K., Karkar, A., Sharif, S., et al. (2021) Corticosteroids in COVID-19 and Non-COVID-19 ARDS: A Systematic Review and Meta-Analysis. Intensive Care Medicine, 47, 521-537. https://doi.org/10.1007/s00134-021-06394-2
|
[286]
|
Ranjbar, K., Moghadami, M., Mirahmadizadeh, A., Fallahi, M.J., et al. (2021) Methylprednisolone or Dexamethasone, Which One Is Superior Corticosteroid in the Treatment of Hospitalized COVID-19 Patients: A Triple-Blinded Randomized Controlled Trial. BMC Infectious Diseases, 21, Article No. 337. https://doi.org/10.1186/s12879-021-06045-3
|
[287]
|
Carbonell, R., Urgelés, S., Rodríguez, A., Bodí, M. and COVID-19 SEMICYUC Working Group (2021) Mortality Comparison between the First and Second/Third Waves among 3,795 Critical COVID-19 Patients with Pneumonia Admitted to the ICU: A Multicentre Retrospective Cohort Study. The Lancet Regional Health—Europe, 11, Article ID: 100243. https://doi.org/10.1016/j.lanepe.2021.100243
|
[288]
|
Wozel, G. and Blasum, C. (2014) Dapsone in Dermatology and Beyond. Archives of Dermatological Research, 306, 103-124. https://doi.org/10.1007/s00403-013-1409-7
|
[289]
|
World Health Organization (2022) World Health Organization Model List of Essential Medicines: 21st List 2019. World Health Organization, Geneva. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists
|
[290]
|
Breedveld, A. and van Egmond, M. (2019) IgA and FcαRI: Pathological Roles and Therapeutic Opportunities. Frontiers in Immunology, 22, Article 553. https://doi.org/10.3389/fimmu.2019.00553
|
[291]
|
Nguyen, V.T. and Chan, L.S. (2022) Dapsone: A Century-Old Medicine and a New Hope for Severe COVID-19. Advances in Infectious Diseases, 12, 50-56. https://doi.org/10.4236/aid.2022.121004
|
[292]
|
Kanwar, B., Lee, C.J. and Lee, J.H. (2021) Specific Treatment Exists for SARS-CoV-2 ARDS. Vaccines (Basel), 9, Article 635. https://doi.org/10.3390/vaccines9060635
|
[293]
|
Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04918914?term=Dapsone&cond=COVID-19&draw=2&rank=2
|
[294]
|
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 (DAP-CORONA). Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04935476?term=Dapsone&cond=COVID-19&draw=2&rank=1
|
[295]
|
Cerqueira, S.R.P.S., Deps, P.D., Cunha, D.V., Bezerra, N.V.F., et al. (2021) The Influence of Leprosy-Related Clinical and Epidemiological Variables in the Occurrence and Severity of COVID-19: A Prospective Real-World Cohort Study. PLOS Neglected Tropical Diseases, 15, e0009635. https://doi.org/10.1371/journal.pntd.0009635
|
[296]
|
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/
|
[297]
|
Bergamaschi, L., Mescia, F., Turner, L., Hanson, A.L., et al. (2021) Longitudinal analysis Reveals That Delayed Bystander CD8+ T Cell Activation and Early Immune Pathology Distinguish Severe COVID-19 from Mild Disease. Immunity, 54, 1257-1275.e8. https://doi.org/10.1016/j.immuni.2021.05.010
|
[298]
|
Gregorova, M., Morse, D., Brignoli, T., Steventon, J., et al. (2020) Post-Acute COVID-19 Associated with Evidence of Bystander T-Cell Activation and a Recurring Antibiotic-Resistant Bacterial Pneumonia. eLife, 9, e63430. https://doi.org/10.7554/eLife.63430.sa2
|
[299]
|
Kanduc, D. (2020) From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry. Antibodies (Basel), 9, Article 33. https://doi.org/10.3390/antib9030033
|
[300]
|
Angileri, F., Légaré, S., Marino Gammazza, A., Conway de Macario, E., Macario, A. and Cappello, F. (2020) Is Molecular Mimicry the Culprit in the Autoimmune Haemolytic Anaemia Affecting Patients with COVID-19? British Journal of Haematology, 190, e92-e93. https://doi.org/10.1111/bjh.16883
|
[301]
|
Marino Gammazza, A., Légaré, S., Lo Bosco, G., Fucarino, A., et al. (2020) Human Molecular Chaperones Share with SARS-CoV-2 Antigenic Epitopes Potentially Capable of Eliciting Autoimmunity against Endothelial Cells: Possible Role of Molecular Mimicry in COVID-19. Cell Stress & Chaperones, 25, 737-741. https://doi.org/10.1007/s12192-020-01148-3
|
[302]
|
Lucchese, G. and Flöel, A. (2020) Molecular Mimicry between SARS-CoV-2 and Respiratory Pacemaker Neurons. Autoimmunity Reviews, 19, Article ID: 102556. https://doi.org/10.1016/j.autrev.2020.102556
|
[303]
|
Adiguzel, Y. (2021) Molecular Mimicry between SARS-CoV-2 and Human Proteins. Autoimmunity Reviews, 20, Article ID: 102791. https://doi.org/10.1016/j.autrev.2021.102791
|
[304]
|
Vojdani, A. and Kharrazian, D. (2020) Potential Antigenic Cross-Reactivity between SARS-CoV-2 and Human Tissue with a Possible Link to an Increase in Autoimmune Diseases. Clinical Immunology (Orlando, FL), 217, Article ID: 108480. https://doi.org/10.1016/j.clim.2020.108480
|
[305]
|
Vojdani, A., Vojdani, E. and Kharrazian, D. (2021) Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins with Tissue Antigens: Implications for Autoimmune Diseases. Frontiers in Immunology, 11, Article ID: 617089. https://doi.org/10.3389/fimmu.2020.617089
|
[306]
|
Lyons-Weiler, J. (2020) Pathogenic Priming Likely Contributes to Serious and Critical Illness and Mortality in COVID-19 via Autoimmunity. Journal of Translational Autoimmunity, 3, Article ID: 100051. https://doi.org/10.1016/j.jtauto.2020.100051
|
[307]
|
Ehrenfeld, M., Tincani, A., Andreoli, L., Cattalini, M., Shoenfeld, Y., et al. (2020) Covid-19 and Autoimmunity. Autoimmunity Reviews, 19, Article ID: 102597. https://doi.org/10.1016/j.autrev.2020.102597
|
[308]
|
Moody, R., Wilson, K., Flanagan, K.L., Jaworowski, A. and Plebanski, M. (2021) Adaptive Immunity and the Risk of Autoreactivity in COVID-19. International Journal of Molecular Sciences, 22, Article 8965. https://doi.org/10.3390/ijms22168965
|
[309]
|
Galeotti, C. and Bayry, J. (2020) Autoimmune and Inflammatory Diseases Following COVID-19. Nature Reviews Rheumatology, 16, 413-414. https://doi.org/10.1038/s41584-020-0448-7.
|